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Background: The essential oil of Pinus koraiensis (EOPK) is biologically active compound obtained from the leaves
of P. koraiensis. The goal of this study was to investigate the anti-cancer mechanism of EOPK in HCT116 colorectal
cancer cells.
Methods: HCT116 cell proliferation was assessed by conducting crystal violet and BrdU assays. To assess the effects
of EOPK on cell migration, we performed a wound-healing assay. Further, the contribution of PAK1 to EOPK-induced
AKT and extracellular signal-regulated kinase (ERK) suppression was assessed by siRNA-mediated PAK1 knockdown.
Changes to the expression and phosphorylation of PAK1 and its effectors were determined by western blotting, and
changes to the actin cytoskeleton were determined by performing an immunofluorescence assay.
Results: EOPK significantly decreased HCT116 cell proliferation and migration, and induced G1 arrest without affecting
normal cells. Additionally, EOPK suppressed the expression of PAK1, and decreased ERK and AKT phosphorylation in
HCT116 cells. Finally, EOPK suppressed β-catenin, cyclin D1, and CDK4/6 expression.
Conclusions: Our studies indicate that EOPK significantly reduced proliferation and migration of colorectal cancer cells.
Furthermore, EOPK suppressed PAK1 expression in a dose-dependent manner, and this suppression of PAK1 led to
inhibition of ERK, AKT, and β-catenin activities. Our findings suggest that EOPK exerts its anticancer activity via
the inhibition of PAK1 expression, suggesting it may be a potent chemotherapeutic agent for colorectal cancer.
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Colorectal cancer is one of the most common forms of
cancer in the Western world [1]. The pathogenesis of
colorectal cancer involves several processes, including
enhanced cell survival, differentiation, and proliferation
[2]. Importantly, K-Ras and B-Raf mutations have been
identified in 40% and 10% of colorectal cancers, respect-
ively [3,4]. Mutations in K-Ras and B-Raf activate the
phosphoinositide 3-kinase (PI3K)/AKT and mitogen-
activated protein kinase (MAPK)/extracellular signal-
regulated kinase (ERK) signaling pathways. In colorectal* Correspondence: strong79@khu.ac.kr
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unless otherwise stated.cancer, overexpression of PI3K/AKTand MAPK/ERK pro-
motes cell survival, proliferation, and migration [5,6].
The p21 activated kinase (PAK) family of proteins has
been identified as a novel target for cancer therapies [7].
PAKs are downstream effectors of the Rho family
GTPases, which regulate cell motility and survival. There
are six isoforms of PAK that are classified into two fam-
ilies, Group I (PAK1-3) and Group II (PAK4-6). Group I
PAKs differ from Group II PAKs in both structure and
mechanisms of activation [8]. PAK1 is an important ef-
fector of Rac and Cdc42 that regulates cell transformation
and tumor proliferation [9]. Activated PAK1 enhances
cell survival and migration via the AKT pathway, and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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MAPK pathway. PAK1 knockdown was shown to in-
hibit the activation of β-catenin in colorectal cancer,
thereby inhibiting Wnt/β-catenin signaling and prolif-
eration [10]. In addition, PAK1 overexpression occurs
in a variety of human cancers, including breast, ovar-
ian, and colorectal cancer. Thus, PAK1 may play an
important role in cell growth, adhesion, migration, and
survival in colorectal cancer, through the activation of
AKT, ERK and β-catenin [11-14].
Pinus koraiensis, generally called the Korean nut pine, is
an evergreen tree found in Korea, China, Japan, and eastern
Russia. Unlike the common Pinaceae plants, P. koraiensis
shows leaves (needles) in fascicles (bundles) of five. Essential
oil derived from P. koraiensis (EOPK) contains a number of
components, including D-limonene, β-pinene, 4-carene,
camphene, β-phellandrene, and fencyl [15]. Much is
known about the role of EOPK in obesity. For ex-
ample, our group previously reported that EOPK has
an >anti-hyperlipidemic effect through the up-regulation
of the low-density lipoprotein receptor and the inhibition
of acyl-coenzyme A [15]. Further, a recent report on
the effects of EOPK indicated that the oil has anti-
obesity and hypolipidemic activity in vitro and in vivo,
using 3 T3-L1 cells and high fat diet-fed rats [16].
Additional studies have shown that EOPK is a poten-
tial anti-diabetic agents and that the nut of P. koraien-
sis has antioxidant activity in vivo [17,18]. Others
studies have demonstrated that the Korean pine nut is
an appetite suppressant, and reduced weight gain in
mice fed a high fat diet [19,20]. Nevertheless, it re-
mains unclear whether EOPK may have an anti-cancer
effect. In the present study, we examined the antitu-
mor mechanism of EOPK in vitro in HCT116 colorec-
tal cancer cells.
Methods
Preparation of essential oil from P. koraiensis leaves
Leaves were harvested from a Korean pine tree that was
more than 30 years old at the end of October in Gangwondo
Honchengun where is famous for producing excellent
Korean pine nuts in Korea. The leaves were purchased
as a dried condition from agricultural corporation,
Beaksongyounglim (Ganwondo, Korea) and identified by
the department of Oriental medicine Biotechnology at the
Kyung Hee University. A voucher specimen (no.KMH-
0081025) was maintained at the herbarium of the depart-
ment of plant physiology at the Kyung Hee University.
EOPK was prepared using a hydrodistillation method [21].
Dried and pulverized P. koraiensis leaves were immersed
in distilled water and steam distilled using an apparatus
with a condenser (Hanil Labtech, Seoul, Korea) for 3 to
4 h at 90°C. The volatile compounds were contained in
the water-soluble fraction, and were allowed to settle for20 min. The essential oil layer was separated and purified
by microfiltration.Cell culture
Colon26L5, a murine colorectal cancer cell line; NIH-
3 T3, a fibroblast cell line; HCT116, a human colorectal
cancer cell line; and HCT15, HT29, and SW620, three
human colorectal adenocarcinoma cell lines, were pur-
chased from American Type Culture Collection (ATCC)
(Rockville, MD), and maintained in RPMI1640 medium
supplemented with 10% fetal bovine serum (FBS), 2 μM
L-glutamine, and penicillin/streptomycin (WelGene,
Deagu, South Korea) in a humidified atmosphere of 5%
CO2 at 37°C.Cytotoxicity assay
Cytotoxicity of EOPK was evaluated by 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
(Sigma Aldrich, St Louis, MO) assay. The cell were
seeded at density of 2 × 104 cells per well in a 96 well
plate, cultured for 24 h, and then treated with various
concentrations of EOPK (0, 25, 50, 100 μg/ml). After
24 h incubation, Per 50 μl of MTT solution (1 mg/ml)
was add to each well and incubated for 2 h at 37°C in
dark. The viable cell number was correlated with the
production of formazan, which was dissolved with di-
methyl sulfoxide (DMSO) and optical density (O.D.) was
measured by microplate reader (Molecular Devices Co.,
Sunnyvale, CA) at 570 nm. Cell viability was calculated by
the following equation. Cell viability(%) = [O.D.(EOPK)-
O.D.(blank)]/[O.D(control)-O.D.(blank)] × 100.Western blot analysis
Cells were lysed in RIPA buffer (50 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxy-
cholate, 1 M EDTA, 1 mM Na3VO4, 1 mM NaF, and
protease inhibitors cocktail). Protein samples were quan-
tified using the Bio-Rad DC protein assay kit II
(Bio-Rad, Hercules, CA), separated by electrophoresis on
an 8 to 10% SDS-PAGE gel, and transferred onto a
Hybond ECL transfer membrane (Amersham Pharmacia,
Piscataway, NJ). The membranes were blocked in 3% non-
fat skim milk and probed with primary antibodies for
PAK1 (Abcam, Cambridge, UK), PI3K (Millipore, Billerica,
MA, USA), phospho-ERK, ERK, β-catenin (Cell Signaling,
Beverly, MA), phospho-AKT, AKT, PTEN (Santa Cruz
Biotechnologies, Santa Cruz, CA), or β-actin (Sigma
Aldrich Co., St. Louis, MO). Membranes were exposed to
horseradish peroxidase (HRP)-conjugated anti-mouse or
rabbit secondary antibodies. Protein expression was exam-
ined by using an enhanced chemiluminescence (ECL) sys-
tem (Amersham Pharmacia, Piscataway, NJ).
Cho et al. BMC Complementary and Alternative Medicine 2014, 14:275 Page 3 of 9
http://www.biomedcentral.com/1472-6882/14/275siRNA transfection
The PAK1 small interfering RNA (siRNA) I and II were
purchased from Cell Signaling. A control siRNA were
purchased from Santa Cruz Biotechnology. To transfect
the siRNA, HCT116 cells were plated at a density of 1 ×
105 cells per well in a six-well plate. Cells were trans-
fected using 100 nM of PAK1 siRNA with siRNA trans-
fection reagent for 48 h. After treatment, cells were
stimulated for Western blot or immunofluorescence
assay.
Wound healing assay
The ability of cells to migrate was assayed by wound
healing assay. The HCT116 cells (1 × 106 cells/ml) were
seeded in a 6-well plate and incubated at 37°C. When
confluent, the cells were scratched with a 200-μL pipette
tip, followed by washing with PBS. The cells were then
treated with EOPK in complete medium for 24 h. After
incubation, the cells were fixed and stained with Diff-
Quick. Randomly chosen fields were photographed under
a fluorescence microscope (AXIO observer A1, ZEISS,
Germany). The number of cells that migrated into the
scratched area was calculated.
Cell growth assay
The cell growth assay was performed to measure the
anti-proliferative effect of EOPK. HCT116 cells (1 × 105
cells/ml) were seeded in a 6-well plate and incubated at
37°C for 24 h, followed by treatment with various con-
centrations of EOPK (0, 25, 50, 100 μg/ml). Cells were
incubated for 5 d, with daily addition of fresh media and
EOPK. To assess proliferation, a crystal violet assay was
performed. The medium was removed carefully by
mild suction, and 2 ml of 1% glutaraldehyde solution
(JUNSEl, Tokyo, Japan) in PBS was added to each well
for 15 min at 37°C. After washing with PBS, 2 ml of 0.05%
crystal violet (Sigma Aldrich, St Louis, MO) was added for
30 min. Following incubation, the crystal violet solution
was removed, and the cells were washed gently with DI
water. The plates were then dried room temperature over-
night. The following day, a 70% ethanol solution was
added (2 ml/well) to each well of the 6-well plate. To
release the crystal violet, the plates were placed on a rotary
shaker for 2 h at room temperature. The optical density
(OD) was measured using a microplate reader (Molecular
Devices Co., Sunnyvale, CA) at 570 nm, with a reference
filter at 405 nm.
Proliferation assay
Cell proliferation in HCT116 cells following EOPK treat-
ment was evaluated using a cell proliferation ELISA kit
(Roche, Swiss) according to the manufacturer’s instruc-
tion. Briefly, after a 24- or 48-h treatment with EOPK,
the cells were treated with bromodeoxyuridine (BrdU,10 μL/well), and incubated for 4 h at 37°C. Following in-
cubation, the BrdU solution was removed, and 200 μl of
FixDenat was added to each well. After incubation for
30 min at room temperature, the FixDenat solution was
removed and 100 μl of anti-BrdU-POD was added to
each well. After washing with PBS three times, 100 μl of
substrate solution was added to each well, and the
optical density was measured at 450 nm using a micro-
plate reader (Molecular Devices Co., Sunnyvale, CA,
USA). All samples were prepared in triplicate, and the
assay was repeated at least three times.
Cell cycle assay
HCT116 cells were treated with EOPK (100 μg/ml) for
24 h. The cells were washed and fixed in 70% ethanol
overnight at −20°C. The following day, the cells were
treated with RNase A (10 mg/ml) for 1 h at 37°C. The
cells were stained by adding 1 ml of propidium iodide
(PI) (50 μg/ml). After filtering with nylon mesh (40 μm),
the DNA contents of stained cells were analyzed using
Cellquest Software (BD Biosciences, San Jose, CA) with
a FACSCalibur flow cytometer (Becton Dickinson,
Franklin Lakes, NJ).
Immunofluorescence assay
Cells were plated onto poly-L-lysine coated coverslips
and fixed with 4% (v/v) methanol-free formaldehyde so-
lution (pH 7.4) at 4°C for 25 min. The cells were perme-
abilized with 0.2% Triton-X 100 in PBS for 5 min, and
blocked in blocking buffer (5% bovine serum albumin,
0.5% Tween-20 in PBS) for 2 h. The cells were incubated
with 200 μl of 100 nM rhodamine phalloidin (Cytoskeleton,
USA) at room temperature in the dark for 30 min. The
DNA was counterstained for 30 s with 300 μl of 100 nM
DAPI in PBS. The slides were mounted with mounting
medium (Vector Laboratories, Inc., Burlingame, CA) and
visualized using the DV Elite™ Imaging System (Deltavision,
Applied Precision, Inc., USA).
Data analyses
All data were shown as mean ± SE. Statistically signifi-
cant differences were evaluated using Student’s t-test
and a Tukey-Kramer multiple-comparison post-test.
Results
PAK1 mediates the MEK/ERK, PI3K/AKT, and Wnt/β-
catenin signaling pathways in colorectal cancer cells
PAK1 expression increases with the progression of colo-
rectal cancer [6]. Therefore, we first assessed PAK1
expression levels in mouse and human colorectal cancer
cell lines by Western blot. PAK1 was expressed in colo-
rectal cancer cell lines including Colon26L5, HCT116,
HCT15, HT29, and SW620 cells. PAK1 expression was
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cancer cells (Figure 1A).
PAK1 is a central node for various oncogenic signaling
pathways, including the Ras/Raf/MAPK/ERK and the
PI3K/AKT signaling pathways [8,22,23]. To assess the
contribution of PAK1 to oncogenic signaling pathways
in colon cancer cells, we knocked down PAK1 expres-
sion with siRNA. siRNA-mediated PAK1 knockdown atten-
uated both β-catenin expression and the phosphorylation of
AKTand ERK (Figure 1B).
EOPK inhibits the expression of PAK1
To investigate the effect of EOPK on PAK1, the cells were
treated with EOPK (100 μg/ml) and Western blotting was
performed. EOPK significantly suppressed the protein ex-
pression of PAK1 in colon cancer cell lines, as shown in
Figure 1C. Further, we assessed the cytotoxicity of EOPKFigure 1 PAK1 mediates MEK/ERK, PI3K/AKT, and Wnt/β-catenin in co
cancer cell lines (human and murine) and normal colon cells extracted from
were transfected with PAK1-siRNA1, PAK1-siRNA2, or control siRNA for 48
determine the expression of PAK1, p-PAK1, AKT, p-AKT, ERK, p-ERK, β-cat
treated with EOPK (100 μg/ml) for 24 h. (D) Cytotoxicity of EOPK was anin NIH-3 T3 cells as a normal cell control. EOPK had no
significant cytotoxic effect in NIH-3 T3 cells (Figure 1D).
EOPK induces G1-arrest and inhibits cell proliferation and
migration
We next performed cell cycle analysis following EOPK
treatment in HCT116 colorectal cancer cells. Cells were
treated with 100 μg/ml of EOPK for 24 h, and were then
analyzed by FACS. Treatment with EOPK significantly
increased G1-arrest in HCT116 cells (Figure 2A).
To investigate whether EOPK suppressed the proliferation
of human colorectal cancer cells, a cell growth assay was
performed. This assay assessed the effect of EOPK on the
long-term (5 d) growth of colorectal cancer cells. As shown
in Figure 2B, EOPK significantly suppressed cell growth in a
dose-dependent manner. Importantly, 100 μg/mL EOPK
suppressed HCT116 growth 99.9%. Consistently, a BrdUlon cancer cells. (A) Basal levels of PAK1 expression in colorectal
mouse tissue were determined by Western blotting. (B) HCT116 cells
h. Cell lysates were prepared and subjected to Western blotting to
enin and β-actin. (C) Various human colorectal cancer cells were
alyzed by MTT assay in NIH-3 T3 cells as a normal cell control.
Figure 2 EOPK inhibits cell proliferation and migration in HCT116 colorectal cancer cells. (A) Cells were treated with EOPK (100 μg/ml) for
24 h. Cell cycle distribution was analyzed by flow cytometry. Bar graphs represent the percentage of sub-G1, G1, S, G2-M phase cells. Data represent
mean ± SD of three independent experiments. *** p < 0.001 compared with untreated control. (B) HCT116 cells were treated with various
concentrations of EOPK (25, 50, 100 μg/ml) and maintained for 5 days. The cells were resolved in 70% ethanol after washing with distilled
water, and crystal violet absorbance was read using a microplate reader. Data represent mean ± SD of three independent experiments. * p < 0.05,
** p < 0.01 and *** p < 0.001 compared with control. (C) HCT116 cells were treated with EOPK for 24 h or 48 h and cell proliferation was measured by
using a BrdU proliferation ELISA kit (Roche, Swiss). (D) Cells were treated with EOPK (25, 50, 100 μg/ml) for 24 h, and cell migration was assayed by
wound healing assay. The number of cells migrating into the scratched area was photographed (×100) and calculated as a percentage of
migration. Data are shown as the mean ± SD of three independent experiments. *** p < 0.001 compared with untreated control.
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eration of HCT116 cells in a concentration- and time-
dependent manner (Figure 2C).
To better understand the inhibitory effect of EOPK on
cell migration, we used a wound-healing assay. As shown
in Figure 2D, EOPK significantly decreased serum-induced
cell migration by 29.4%, 48.6% and 85.8% as compared tothe untreated control at 25, 50, and 100 μg/ml EOPK,
respectively.
EOPK attenuates β-catenin expression and AKT, and ERK
phosphorylation via PAK1
To assess whether the PI3K/AKT, MAPK/ERK and
Wnt/β-catenin signaling pathways contributed to the
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of PAK1, β-catenin, phosphor-AKT, and phosphor-ERK
were investigated by Western blotting. EOPK remarkably
suppressed the phosphorylation of AKT, ERK, and
PAK1, as well as the expression of β-catenin in HCT116
colorectal cancer cells (Figure 3A). We previously showed
that siRNA knockdown of PAK1 reduced phosphorylation
AKT and ERK (Figure 1B). This is consistent with previ-
ous reports, in which, knockdown of PAK1 in colorectal
cancer cells by shRNA suppressed cell proliferation via
the ERK and AKT pathways [24,25]. Interestingly, PAK1
knockdown enhanced the inhibitory effect of EOPK on β-
catenin expression and phosphorylation of AKT and ERK
in HCT116 cells (Figure 3B).
PAK1 mediates EOPK-induced G1 arrest, suppression of cell
proliferation and migration, and altered actin cytoskeletal
arrangement
We next assessed whether EOPK-mediated G1 arrest is
dependent on PAK1 inhibition. Knockdown of PAK1 by
siRNA reduced the expression of G1 regulatory proteins,
such as cyclin D1, CDK4, and CDK6 (Figure 4A). Conse-
quently, PAK1 knockdown enhanced EOPK-mediatedFigure 3 EOPK suppresses AKT and ERK phosphorylation and β-caten
cells. (A) HCT116 cells were treated with various concentrations of EOPK (2
or a control siRNA for 48 h and incubated in the presence or absence of E
prepared and subjected to Western blotting to determine the express
density of PAK1, p-PAK1, AKT, p-AKT, ERK, p-ERK, and β-catenin was quantifiedinhibition of proliferation, as assessed by cell growth
assay (Figure 4B). Further, PAK1 knockdown also en-
hanced EOPK-mediated cell migration, as determined
using a wound healing assay (Figure 4C). PAK1 plays a
critical role in migration, invasion, and proliferation
through its regulation of actin cytoskeletal reorganization
[26,27]. To determine whether the EOPK-mediated sup-
pression of migration was due to inhibition of PAK1-
mediated actin cytoskeletal rearrangement, an immuno-
fluorescence assay was performed. In tis assay, rhodamine
phalloidin was used to detect F-actin. Knockdown of
PAK1 by siRNA reduced basal spread of cells and in-
creased cell rounding. In addition, knockdown of PAK1
enhanced EOPK-mediated alterations of actin cytoskel-
eton in HCT116 colorectal cancer cells (Figure 4D).
Discussion
Our findings show that EOPK efficaciously inhibits the
proliferation and migration of colon cancer cells in vitro.
Fluorouracil (5-FU) is a standard therapeutic agent used
in the treatment of colorectal cancer since the 1950s.
However, not all of patients respond to 5-FU [28]. Thus,
recent work identifying the antitumor effects of naturalin expression via PAK1 inhibition in HCT116 colorectal cancer
5, 50, 100 μg/ml). (B) HCT116 cells were transfected with PAK1-siRNA
OPK (100 μg/ml) for 24 h. For both experiments, cell lysates were
ion of PAK1, p-PAK1, AKT, p-AKT, ERK, p-ERK, β-catenin and β-actin. Band
using Gelpro analyzer (Media Cybernetics, Bethesda, MD, USA).
Figure 4 PAK1 siRNA enhances the inhibitory effect of EOPK on the cell proliferation and migration. (A) HCT116 cells were transfected
with PAK1-siRNA for 48 h and were incubated in the presence or absence of EOPK (100 μg/ml) for 24 h. Cell lysates were prepared and subjected
to Western blotting to determine the expression of Cyclin D1, CDK4, CDK6 and β-actin. (B) HCT116 cells were transfected with PAK1-siRNA for
24 h and treated with EOPK (100 μg/ml) for 5 days. The cells were resolved in 70% ethanol after washing with distilled water, and crystal violet
absorbance was read using a microplate reader. Data represent mean ± SD of three independent experiments. * p< 0.05, ** p< 0.01 and *** p< 0.001
compared with control. ### p< 0.001 compared with control-siRNA and PAK1-siRNA. (C) Cell migration was assessed by a wound healing assay. The
number of cells migrated into the scratched area was calculated. Data are shown as the mean ± SD of three independent experiments. *** p < 0.001
compared with untreated control. ### p < 0.001 compared with control-siRNA and PAK1-siRNA. (D) Fixed cells were stained with rhodamine phalloidin
and DAPI, and imaged using a DV Elite™ Imaging System (Deltavision, Applied Precision, Inc., USA). Arrow indicates lamellipodia. Arrow
indicates lamellipodia.
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therapeutic for the treatment of colorectal cancer. Many
extracts from vegetables, fruits, and plants, including
epigallocatechin gallate (EGCG) and Morus alba leaf ex-
tract, can inhibit cell proliferation and survival, andinduce apoptosis in colorectal cancer cell [29,30]. Here,
we show that EOPK significantly decreases proliferation
and migration in colorectal cancer cells, without affect-
ing normal cells. Recent reports have indicated that
EOPK has anti-obesity and hypolipidemic effects [15,16].
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nuts, and cones have been shown to have biological effi-
cacy [17,18,20,31,32]. However, the effect of EOPK on
tumor proliferation and survival has not been examined
to date.
PAK1 was recently shown to be an effective thera-
peutic target for cancer treatment [33]. Interestingly, we
found that EOPK treatment significantly reduced PAK1
expression in several colon cancer cells. It is well known
that PAK1 mediates cell proliferation, migration, inva-
sion, and survival through the ERK and AKT signaling
pathways [6]. Thus, to confirm the involvement of PAK1
in EOPK-mediated inhibition of cell proliferation and
migration, we analyzed the effects of EOPK on AKT and
ERK phosphorylation in HCT116 cells. Knockdown of
PAK1 with siRNA enhanced the inhibitory effect of
EOPK on AKT and ERK phosphorylation in HCT116 cells.
Further, PAK1 knockdown enhanced EOPK-mediated in-
hibition of PAK1 activity. Combined, these data suggest
that EOPK suppresses cell growth and migration via the in-
hibition of PAK1, AKT, and ERK signaling in colon cancer
cells. In addition, PAK1 is known to be involved in macro-
phage spreading and migration, and previous work indi-
cates that PAK1 acts via ERK1/2 to regulate lamellipodia
formation [34]. We showed that EOPK significantly sup-
pressed actin cytoskeletal rearrangement in HCT116
colorectal cancer cells. Furthermore, EOPK signifi-
cantly decreased proliferation and migration, induced
G1-arrest, and inhibited the expression of phospho-
ERK, phospho-AKT, β-catenin, cyclin D1 and CDK4/6
in colorectal cancer cells.Conclusions
In summary, our results demonstrate that EOPK reduces
proliferation of HCT116 cells through G1 arrest, without
affecting normal cells. EOPK inhibits cell migration and
alters cytoskeletal structure, through the reduction of
basal spread and cell elongation and increased cell
rounding. EOPK-induced G1 arrest, inhibited cell prolif-
eration and migration, and suppressed actin cytoskeletal
rearrangement via the inhibition of PAK1. This inhib-
ition of PAK1 resulted in decreases in ERK and AKT
phosphorylation and β-catenin expression. Combined,
our findings provide evidence that EOPK may be a novel
therapeutic for the treatment of colorectal cancer. There
is great potential for the development of novel chemo-
therapeutics from the leaves of P. koraiensis.Abbreviations
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